Cevimeline
Evoxac (cevimeline) is a small molecule pharmaceutical. Cevimeline was first approved as Evoxac on 2000-01-11. It is used to treat xerostomia in the USA. It is known to target muscarinic acetylcholine receptor M2, muscarinic acetylcholine receptor M1, muscarinic acetylcholine receptor M4, and muscarinic acetylcholine receptor M3.
| Trade Name | Evoxac |
|---|---|
| Common Name | Cevimeline |
| Indication | xerostomia |
| Drug Class | Cholinergic agonists (arecoline derivatives used in treatment of Alzheimer disease) |
